Identification

Name
Clidinium
Accession Number
DB00771  (APRD00737)
Type
Small Molecule
Groups
Approved
Description

Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.

Structure
Thumb
Synonyms
  • 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane
  • 3-hydroxy-1-methylquinuclidinium benzilate ester
  • Bromure de Clidinium
  • Bromuro de clidinio
  • Clidinii Bromidum
  • Clidinium bromid
  • N-methyl quinuclidinyl benzilate
External IDs
Ro 2-3773
Product Ingredients
IngredientUNIICASInChI Key
Clidinium Bromide91ZQW5JF1Z3485-62-9GKEGFOKQMZHVOW-UHFFFAOYSA-M
Product Images
International/Other Brands
Dolibrax (Roche) / Porsucon (Ying Yuan) / Quarzan (Roche) / Sedaspa (Hua Shin)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ChloraxClidinium Bromide (2.5 mg) + Chlordiazepoxide hydrochloride (5 mg)CapsuleOralAa Pharma Inc1984-12-31Not applicableCanada
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2016-04-152017-05-12Us
Chlordiazepoxide Hydrochloride And Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralAcella Pharmaceuticals, LLC2011-08-302016-11-29Us
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralAvera Mc Kennan Hospital2016-01-18Not applicableUs
Chlordiazepoxide Hydrochloride And Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralA S Medication Solutions2011-08-302017-06-20Us
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralBi Coastal Pharma International Limited Liability Company2011-05-04Not applicableUs
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralBi Coastal Pharmaceutical Corporation2011-05-04Not applicableUs
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralOceanside Pharmaceuticals2009-09-23Not applicableUs
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralEci Pharmaceuticals Llc2011-05-04Not applicableUs
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralCameron Pharmaceuticals1966-09-01Not applicableUs
Categories
UNII
BO76JF850N
CAS number
7020-55-5
Weight
Average: 352.4467
Monoisotopic: 352.191268703
Chemical Formula
C22H26NO3
InChI Key
HOOSGZJRQIVJSZ-NNBUQUNQSA-N
InChI
InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1/t17-,20?,23+
IUPAC Name
(1s,4s)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methyl-1-azabicyclo[2.2.2]octan-1-ium
SMILES
C[[email protected]@+]12CC[[email protected]@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.

Structured Indications
Pharmacodynamics

Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.

Mechanism of action

Inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites primarily by inhibiting the M1 muscarinic receptors.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Signs of toxicity include confusion, paralytic ileus, urinary hesitancy/retention, and blurred vision.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clidinium.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clidinium.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clidinium.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Clidinium.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clidinium.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Clidinium is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clidinium.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Clidinium.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Clidinium.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Clidinium.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Clidinium.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clidinium.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clidinium.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clidinium.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clidinium.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clidinium.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Clidinium.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clidinium.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Clidinium.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clidinium.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Clidinium.Investigational, Vet Approved
AzelastineClidinium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Clidinium.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Clidinium.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Clidinium.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Clidinium.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clidinium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Clidinium is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clidinium.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Clidinium.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Clidinium.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Clidinium is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Clidinium.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clidinium.Approved, Investigational
BuprenorphineClidinium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clidinium.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clidinium.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Clidinium.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Clidinium.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Clidinium.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Clidinium.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clidinium.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Clidinium.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clidinium.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clidinium.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Clidinium.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clidinium.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clidinium.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clidinium.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clidinium.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Clidinium.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clidinium.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Clidinium is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clidinium.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clidinium.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clidinium.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clidinium.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Clidinium is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Clidinium.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Clidinium.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clidinium is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clidinium is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clidinium.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Clidinium.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clidinium.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Clidinium.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Clidinium.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Clidinium.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clidinium.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Clidinium is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clidinium.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clidinium.Approved
DantroleneThe risk or severity of adverse effects can be increased when Clidinium is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clidinium.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Clidinium is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Clidinium.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clidinium.Approved
DesipramineThe risk or severity of adverse effects can be increased when Clidinium is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Clidinium is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Clidinium is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Clidinium.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clidinium.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clidinium.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clidinium.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clidinium.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Clidinium.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clidinium.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Clidinium.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Clidinium is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clidinium.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clidinium.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clidinium.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Clidinium is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clidinium.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clidinium.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Clidinium.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Clidinium.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Clidinium is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Clidinium.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Clidinium.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Clidinium is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clidinium.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Clidinium.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clidinium.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clidinium.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Clidinium.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clidinium.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Clidinium.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Clidinium is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clidinium.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clidinium.Approved
EthanolClidinium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clidinium.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clidinium.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clidinium.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clidinium.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Clidinium.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clidinium.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clidinium.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Clidinium.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Clidinium.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Clidinium.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clidinium.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Clidinium is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Clidinium.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Clidinium is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Clidinium is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clidinium.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clidinium.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Clidinium is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Clidinium is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Clidinium.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clidinium.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Clidinium is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clidinium.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Clidinium is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clidinium.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clidinium.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clidinium.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clidinium.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clidinium.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clidinium.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Clidinium is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clidinium.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clidinium.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Clidinium is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Clidinium.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Clidinium.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Clidinium.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Clidinium is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Clidinium.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clidinium.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clidinium.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Clidinium.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clidinium.Approved
HydrocodoneClidinium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clidinium.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Clidinium is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clidinium.Approved
IndalpineThe risk or severity of adverse effects can be increased when Clidinium is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Clidinium.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clidinium.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clidinium.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clidinium.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clidinium.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clidinium.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Clidinium is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clidinium.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Clidinium is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Clidinium is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Clidinium is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clidinium.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Clidinium is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clidinium.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clidinium.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Clidinium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Clidinium.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Clidinium.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Clidinium.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clidinium.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Clidinium.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clidinium.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clidinium.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Clidinium is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Clidinium.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Clidinium.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Clidinium.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Clidinium.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Clidinium.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Clidinium.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clidinium.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clidinium.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Clidinium.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clidinium.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clidinium.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Clidinium.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Clidinium.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clidinium.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clidinium.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clidinium.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clidinium.Approved
MethotrimeprazineClidinium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clidinium.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Clidinium is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clidinium.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clidinium.Approved
MetyrosineClidinium may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clidinium.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Clidinium is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved, Investigational
MirtazapineClidinium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Clidinium.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clidinium.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clidinium.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Clidinium is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clidinium.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Clidinium.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Clidinium.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Clidinium.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clidinium.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clidinium.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clidinium.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clidinium.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Clidinium.Approved, Illicit
OrphenadrineClidinium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Clidinium.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clidinium.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Clidinium.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clidinium.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clidinium.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clidinium.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clidinium.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clidinium.Approved
ParaldehydeClidinium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Clidinium is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Clidinium.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clidinium.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clidinium.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Clidinium.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Clidinium.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clidinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clidinium.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Clidinium.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Clidinium.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clidinium.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Clidinium.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Clidinium.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clidinium.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Clidinium.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clidinium.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Clidinium is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Clidinium.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Clidinium is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Clidinium is combined with Pomalidomide.Approved
PramipexoleClidinium may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clidinium.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clidinium.Approved, Illicit
PregabalinThe therapeutic efficacy of Clidinium can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Clidinium.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Clidinium is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Clidinium.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clidinium.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Clidinium.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Clidinium is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Clidinium.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clidinium.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clidinium.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Clidinium.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clidinium.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Clidinium.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Clidinium.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clidinium.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clidinium.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Clidinium.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Clidinium.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Clidinium is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clidinium.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clidinium.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clidinium.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Clidinium.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Clidinium.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Clidinium.Vet Approved
RopiniroleClidinium may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clidinium.Approved
RotigotineClidinium may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clidinium.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clidinium.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clidinium.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Clidinium.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Clidinium.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Clidinium is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clidinium.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
StiripentolThe risk or severity of adverse effects can be increased when Clidinium is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clidinium.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clidinium.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Clidinium.Experimental
SuvorexantClidinium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Clidinium.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Clidinium is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clidinium.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Clidinium is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clidinium.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clidinium.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clidinium.Investigational
ThalidomideClidinium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clidinium.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Clidinium.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clidinium.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clidinium.Approved
TiagabineThe risk or severity of adverse effects can be increased when Clidinium is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Clidinium.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Clidinium.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Clidinium.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clidinium.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clidinium.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Clidinium.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clidinium.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clidinium.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clidinium.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Clidinium.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clidinium.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Clidinium.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Clidinium.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clidinium.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Clidinium.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clidinium.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clidinium.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clidinium.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clidinium.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Clidinium is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Clidinium.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Clidinium is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Clidinium.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clidinium.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Clidinium.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Clidinium.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clidinium.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Clidinium is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Clidinium is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Clidinium.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Clidinium.Vet Approved
ZolpidemClidinium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Clidinium is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Clidinium.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Clidinium.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clidinium.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Sternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche, Inc.

General References
Not Available
External Links
Human Metabolome Database
HMDB14909
KEGG Compound
C07853
PubChem Compound
2784
PubChem Substance
46507814
ChemSpider
26330531
BindingDB
50055977
ChEBI
3743
Therapeutic Targets Database
DAP001117
PharmGKB
PA164781044
IUPHAR
366
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clidinium
ATC Codes
A03CA02 — Clidinium and psycholeptics

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral
Prices
Unit descriptionCostUnit
Quarzan 5 mg capsule0.3USD capsule
Quarzan 2.5 mg capsule0.23USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)240-241 °CSternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche, Inc.
Predicted Properties
PropertyValueSource
Water Solubility0.000377 mg/mLALOGPS
logP-0.5ALOGPS
logP-1.1ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)11.05ChemAxon
pKa (Strongest Basic)-4.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity112.14 m3·mol-1ChemAxon
Polarizability38.76 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9243
Blood Brain Barrier+0.9142
Caco-2 permeable+0.671
P-glycoprotein substrateSubstrate0.8526
P-glycoprotein inhibitor INon-inhibitor0.7661
P-glycoprotein inhibitor IINon-inhibitor0.9576
Renal organic cation transporterInhibitor0.6314
CYP450 2C9 substrateNon-substrate0.7781
CYP450 2D6 substrateNon-substrate0.6956
CYP450 3A4 substrateSubstrate0.6095
CYP450 1A2 substrateNon-inhibitor0.9528
CYP450 2C9 inhibitorNon-inhibitor0.9459
CYP450 2D6 inhibitorInhibitor0.6154
CYP450 2C19 inhibitorNon-inhibitor0.9577
CYP450 3A4 inhibitorNon-inhibitor0.9504
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9889
Ames testNon AMES toxic0.8557
CarcinogenicityNon-carcinogens0.933
BiodegradationReady biodegradable0.7763
Rat acute toxicity2.4948 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8162
hERG inhibition (predictor II)Non-inhibitor0.6539
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Quinuclidines / Piperidines / Tetraalkylammonium salts / Tertiary alcohols / Carboxylic acid esters / Monocarboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic salts / Organic oxides
show 5 more
Substituents
Diphenylmethane / Quinuclidine / Piperidine / Quaternary ammonium salt / Tetraalkylammonium salt / Tertiary alcohol / Carboxylic acid ester / Organoheterocyclic compound / Azacycle / Carboxylic acid derivative
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
carboxylic ester, organic cation, quaternary ammonium ion (CHEBI:3743)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 17:18